A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations
Worldwide more than half a million new cases of lung cancer are diagnosed annually. About
80% of these tumours are of non-small cell histological type. Surgery is the treatment of
choice, but only about 20% of tumours are suitable for potentially curative resection.
Concurrent chemoradiotherapy is the standard treatment for locally advanced NSCLC. When
Iressa was used in the first-line treatment of advanced NSCLC with EGFR mutations positive,
the 12-month rates of progression-free survival were 24.9%. Therefore, we speculate that the
EGFR mutations in patients with locally advanced NSCLC, Gefitinib combined with radiotherapy
may be better than chemoradiotherapy. We design the study to access the effect and safety of
radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung
cancer with harboring active EGFR mutations.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate (RR)
Beijing Cancer Hospital
China: Ethics Committee